annual cash & cash equivalents:
$931.25M+$297.12M(+46.85%)Summary
- As of today (September 17, 2025), MDGL annual cash & cash equivalents is $931.25 million, with the most recent change of +$297.12 million (+46.85%) on December 31, 2024.
- During the last 3 years, MDGL annual cash & cash equivalents has risen by +$660.90 million (+244.47%).
- MDGL annual cash & cash equivalents is now at all-time high.
Performance
MDGL Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$802.02M-$46.04M(-5.43%)Summary
- As of today (September 17, 2025), MDGL quarterly cash & cash equivalents is $802.02 million, with the most recent change of -$46.04 million (-5.43%) on June 30, 2025.
- Over the past year, MDGL quarterly cash & cash equivalents has dropped by -$260.77 million (-24.54%).
- MDGL quarterly cash & cash equivalents is now -24.54% below its all-time high of $1.06 billion, reached on June 30, 2024.
Performance
MDGL quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
MDGL Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +46.9% | -24.5% |
| 3 y3 years | +244.5% | +278.7% |
| 5 y5 years | +112.1% | +108.7% |
MDGL Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +244.5% | -24.5% | +423.5% |
| 5 y | 5-year | at high | +244.5% | -24.5% | +423.5% |
| alltime | all time | at high | >+9999.0% | -24.5% | >+9999.0% |
MDGL Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $802.02M(-5.4%) |
| Mar 2025 | - | $848.07M(-8.9%) |
| Dec 2024 | $931.25M(+46.9%) | $931.25M(-7.2%) |
| Sep 2024 | - | $1.00B(-5.6%) |
| Jun 2024 | - | $1.06B(+0.4%) |
| Mar 2024 | - | $1.06B(+67.0%) |
| Dec 2023 | $634.13M(+76.7%) | $634.13M(+172.9%) |
| Sep 2023 | - | $232.35M(-22.1%) |
| Jun 2023 | - | $298.42M(-9.4%) |
| Mar 2023 | - | $329.48M(-8.2%) |
| Dec 2022 | $358.77M(+32.7%) | $358.77M(+134.2%) |
| Sep 2022 | - | $153.19M(-27.7%) |
| Jun 2022 | - | $211.77M(-3.7%) |
| Mar 2022 | - | $219.95M(-18.6%) |
| Dec 2021 | $270.35M(-4.9%) | $270.35M(-9.6%) |
| Sep 2021 | - | $299.14M(-7.6%) |
| Jun 2021 | - | $323.85M(+5.4%) |
| Mar 2021 | - | $307.22M(+8.1%) |
| Dec 2020 | $284.15M(-35.3%) | $284.15M(-15.4%) |
| Sep 2020 | - | $335.94M(-12.6%) |
| Jun 2020 | - | $384.38M(-5.9%) |
| Mar 2020 | - | $408.51M(-7.0%) |
| Dec 2019 | $439.05M(-9.2%) | $439.05M(-3.2%) |
| Sep 2019 | - | $453.61M(-2.7%) |
| Jun 2019 | - | $466.40M(-2.4%) |
| Mar 2019 | - | $477.82M(-1.2%) |
| Dec 2018 | $483.72M(+152.6%) | $483.72M(-1.0%) |
| Sep 2018 | - | $488.54M(-0.4%) |
| Jun 2018 | - | $490.31M(+168.2%) |
| Mar 2018 | - | $182.82M(-4.5%) |
| Dec 2017 | $191.53M(+372.9%) | $191.53M(+208.2%) |
| Sep 2017 | - | $62.14M(-7.5%) |
| Jun 2017 | - | $67.17M(+67.4%) |
| Mar 2017 | - | $40.13M(-0.9%) |
| Dec 2016 | $40.50M(>+9900.0%) | $40.50M(+2.4%) |
| Sep 2016 | - | $39.56M(-8.0%) |
| Jun 2016 | - | $43.02M(-17.3%) |
| Mar 2016 | - | $52.04M(>+9900.0%) |
| Dec 2015 | $306.20K | $306.20K(-99.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2015 | - | $88.25M(-10.3%) |
| Jun 2015 | - | $98.33M(+28.4%) |
| Mar 2015 | - | $76.61M(-21.6%) |
| Dec 2014 | $97.69M(+6.8%) | $97.69M(-18.1%) |
| Sep 2014 | - | $119.28M(+6.4%) |
| Jun 2014 | - | $112.06M(+42.2%) |
| Mar 2014 | - | $78.79M(-13.9%) |
| Dec 2013 | $91.48M(-9.1%) | $91.48M(+71.4%) |
| Sep 2013 | - | $53.38M(-24.0%) |
| Jun 2013 | - | $70.20M(-22.3%) |
| Mar 2013 | - | $90.39M(-10.1%) |
| Dec 2012 | $100.60M(+153.2%) | $100.60M(+82.4%) |
| Sep 2012 | - | $55.14M(+23.5%) |
| Jun 2012 | - | $44.66M(-22.2%) |
| Mar 2012 | - | $57.39M(+44.5%) |
| Dec 2011 | $39.73M(-22.1%) | $39.73M(-21.6%) |
| Sep 2011 | - | $50.66M(-19.4%) |
| Jun 2011 | - | $62.89M(+56.3%) |
| Mar 2011 | - | $40.23M(-21.1%) |
| Dec 2010 | $50.97M(+15.4%) | $50.97M(-5.8%) |
| Sep 2010 | - | $54.12M(+11.2%) |
| Jun 2010 | - | $48.66M(-16.0%) |
| Mar 2010 | - | $57.92M(+31.2%) |
| Dec 2009 | $44.16M(-15.2%) | $44.16M(-14.8%) |
| Sep 2009 | - | $51.83M(-14.6%) |
| Jun 2009 | - | $60.70M(-28.5%) |
| Mar 2009 | - | $84.90M(+45.0%) |
| Dec 2008 | $52.05M(-55.0%) | - |
| Sep 2008 | - | $58.55M(-26.3%) |
| Jun 2008 | - | $79.46M(-20.0%) |
| Mar 2008 | - | $99.29M(+105.0%) |
| Dec 2007 | $115.58M(+243.1%) | - |
| Sep 2007 | - | $48.42M(-25.1%) |
| Jun 2007 | - | $64.61M(+9.2%) |
| Dec 2006 | $33.69M(+41.5%) | - |
| Sep 2006 | - | $59.19M(+148.6%) |
| Dec 2005 | $23.81M(-44.3%) | $23.81M(-10.1%) |
| Mar 2005 | - | $26.49M |
| Dec 2004 | $42.74M(+18.5%) | - |
| Dec 2003 | $36.06M | - |
FAQ
- What is Madrigal Pharmaceuticals, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Madrigal Pharmaceuticals, Inc.?
- What is Madrigal Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
- What is Madrigal Pharmaceuticals, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Madrigal Pharmaceuticals, Inc.?
- What is Madrigal Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
What is Madrigal Pharmaceuticals, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of MDGL is $931.25M
What is the all time high annual cash & cash equivalents for Madrigal Pharmaceuticals, Inc.?
Madrigal Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $931.25M
What is Madrigal Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, MDGL annual cash & cash equivalents has changed by +$297.12M (+46.85%)
What is Madrigal Pharmaceuticals, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of MDGL is $802.02M
What is the all time high quarterly cash & cash equivalents for Madrigal Pharmaceuticals, Inc.?
Madrigal Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $1.06B
What is Madrigal Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, MDGL quarterly cash & cash equivalents has changed by -$260.77M (-24.54%)